Crinetics Pharmaceuticals Inc [CRNX] stock prices are up 3.04% to $39.38 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRNX shares have gain 1.89% over the last week, with a monthly amount drifted -26.97%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on January 22, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $55 for it. Previously, Citigroup started tracking the stock with Buy rating on March 06, 2024, and set its price target to $68. On January 16, 2024, Morgan Stanley initiated with a Overweight rating and assigned a price target of $50 on the stock. Jefferies started tracking the stock assigning a Hold rating and suggested a price target of $35 on December 21, 2023. In a note dated August 31, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $40 on this stock.
The stock price of Crinetics Pharmaceuticals Inc [CRNX] has been fluctuating between $35.51 and $62.53 over the past year. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $39.38 at the most recent close of the market. An investor can expect a potential return of 75.22% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -295.87%, Pretax Profit Margin comes in at -267.48%, and Net Profit Margin reading is -267.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.36 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.22 points at the first support level, and at 37.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.15, and for the 2nd resistance point, it is at 40.91.
Ratios To Look Out For
It’s worth pointing out that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX]’s Current Ratio is 16.38. Also, the Quick Ratio is 16.38, while the Cash Ratio stands at 5.92.
Transactions by insiders
Recent insider trading involved Pizzuti Dana, Chief Med and Dev Officer, that happened on Jan 03 ’25 when 15000.0 shares were sold. Officer, DANA J PIZZUTI completed a deal on Jan 03 ’25 to buy 15000.0 shares. Meanwhile, President & CEO Struthers Richard Scott sold 10000.0 shares on Dec 02 ’24.
